Search Results
Public Perception of Public Health Wireless Emergency Alerts
The objectives of this study are to understand attitudes, emotional response, and behavioral intention related to receiving COVID-19 public health messaging via the Wireless Emergency Alert system.
Received a Wireless Emergency Alert in November
Did not receive a Wireless Emergency Alert in November
Protocol NRG-LU007: RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC: RAPTOR trial (NCT # NCT04402788) (PSCI# 20-118)
The purpose of this study is to compare the usual treatment of the immune therapy drug atezolizumab alone, to using radiation therapy plus the usual treatment. The addition of radiation to the usual treatment could shrink your cancer or prevent it from returning. This study will help the study doctors find out if this different approach is better, the same or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study approach increases the life of patients or extends your time without disease compared to the usual approach.
The purpose of this study is to compare the usual treatment of the immune therapy drug atezolizumab alone, to using radiation therapy plus the usual treatment.
measurable disease (per RECIST) and 3 or fewer observable liver metastases and no evidence of progressive disease at enrollment
Patients presenting with a pleural effusion will be eligible if thoracentesis is cytologically negative and non-bloody
ECOG Performance Status of 0-2 at the time of registration
Age ≥ 18
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 5 years prior to randomization
Chronic obstructive pulmonary disease (COPD) requiring chronic oral steroid therapy of > 10 mg prednisone daily or equivalent at the time of registration
Patients who have had immunotherapy-induced pneumonitis
History of recent myocardial infarction within 6 months prior to registration
A PROSPECTIVE MULTICENTER STUDY TO ASSESS THE CLINICAL OUTCOMES OF CURRENT PHACOEMULSIFICATION APPROACH TO CATARACT EXTRACTION VERSUS THE MICOR SYSTEM DEVICE USING LOW ENERGY LENS EXTRACTION IN PATIENTS UNDERGOING CATARACT SURGERY
Research study to assess visual outcomes after cataract surgery between different devices. 3 trial groups open to males and females over the age of 18 who are to undergo cataract surgery.
There will be 3 in person visits per surgery eye.Vision will be checked at 2 of these visitsCataract surgery will be done at 1 of these visits
Must have a cataract that qualifies for surgery
Not Pregnant
Other eye conditions may not be allowed to participate, study coordinator will discuss further
Self and community spiritual resilience in LGBTQ+ and gender nonconforming individuals
The goal of this research is an assessment of spirituality as a coping mechanism related to self and community stigmatization faced by gender nonconforming individuals and those in the LGBTQ+ community. Examination of discriminatory events, spiritual coping, and sense of community belonging will also be conducted.
Participants will complete a series of online questionnaires
Not straight but don't identify as LGBTQ+
Effect of Nitrate Supplementation on Cerebrovascular function and Cognitive Function in Older Adults with Metabolic Syndrome
The aim of this study is to determine the impact of cardiometabolic disease risk factors on cognitive performance and brain vascular function, as well as, to see if beetroot juice supplementation can improve these outcomes and reduce risk of cognitive decline and brain vascular dysfunction that is seen with aging and disease.
Participants with and without high blood pressure, high cholesterol, and high blood sugar will be recruited. These are all considered cardiovascular disease risk factors.Individuals without multiple cardiovascular disease risk factors will have 2 visits and complete cognitive and blood vessel function assessments. There involves a blood draw in each visit. All study assessments are non-invasive. Total compensation is $30. Individuals with cardiovascular disease risk factors will have 5 total visits and complete cognitive and blood vessel function assessments. Additionally, participants will drink beetroot juice for 4 weeks to determine the potential health benefits on cognitive, blood vessel function, and metabolic health. There will involve blood draws and all assessments are non-invasive. Total compensation is up to $170.
$30 -170
high blood pressure and/or high cholesterol and/or high cholesterol
the above criteria does not apply for the control group
Severe visual impairment
Individuals with any overt cardiovascular, hematologic, pulmonary, renal, musculoskeletal, and/or neurological disease(s)
Parent-to-child anxiety transmission in early childhood: Capturing in-the-moment mechanisms through emotion modeling and biological synchrony
Anxiety can emerge as early as pre-school age (4-6) and is often linked to anxiety in the parent. This study will examine patterns of brain and behavioral synchrony in parent-child pairs as they complete puzzles together and other social activities.
This is a longitudinal study examining the role that parent-child synchrony and emotional modeling plays in the transmission of anxiety. Participants will complete yearly laboratory visits and 6-month follow-up visits. The yearly laboratory visits (V1,3,5) will include a battery of tasks and questionnaires, but the six-month follow-up visits(V2,4) will only include online questionnaires. Participants at both Penn State and Washington University, St. Louis will follow the same procedures.
Participating families will be given $100 at each of V1 and V3, $25 for each of the follow-ups at V2 and V4, $100 and a $50 completion bonus at V5, for a total amount of $400.
Children without serious medical issues or complications
Parents or caregivers aged 18 or older
Children diagnosed with any neurological disorders and/or diseases
Children unable to communicate at a level similar to their peers
Children that have experienced a head injury with a loss of consciousness
Children 0 to 3 years of age; Children 7 and older
Understanding rideshare passengers’ awareness and attitudes toward Rideshare drivers’ safety
In prior research, it was found that the major source of drivers’ feelings of lack of safety is the passenger (Almoqbel and Wohn, 2020); in this research, we aim to understand the perceptions of rideshare passengers of the drivers’ safety. We plan to interview 30 rideshare passengers from the U.S. We ask them questions about their behavior in the rideshare cars and their perception of the driver's safety. The results will provide insights into passengers’ behaviors that could be influenced by platforms to enhance the safety of both app users, the driver, and the passenger.
We are researchers to work on understanding users’ rideshare experience. If you often use rideshare apps (e.g., almost every week), such as Uber or Lyft, please consider participating in our 30 mins to 1 hours interview to share your rideshare and app usage experience. We can have a remote interview with Zoom, Discord, phone call, or Skype.
$15
English-Speaking
Non-English speaking
Phase II, questionnaire for “BRITE Synergy: Developing and Validating a Framework for Measuring Resilience in Low-Income Housing in the Post-Pandemic World”
This study includes the questionnaire related to "BRITE Synergy: Developing and Validating a Framework for Measuring Resilience in Low-Income Housing in the Post-Pandemic World" which has been previously submitted. The objective of this part of the research is examining the extent to which energy burden linked to the use of inefficient appliance within the context of a changing climate can be a good proxy for community resilience and if the ongoing building electrification drive.
Participants will be asked to complete an online survey via a link that will be accessed.
10 random participants will receive $20 gif cards.
Subjects must be living in the US
Living outside the US
Phase III IGRT and SBRT VS IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer (NRG-GU005) (PSCI# 19-073)
The purpose of this study is to compare any good and bad effects of using stereotactic body radiation therapy (SBRT), a technique that gives treatment in a shorter amount of time compared to the usual radiation therapy. SBRT is experimental for treating this type of cancer. SBRT uses special equipment to position a participant and precisely deliver radiation to tumors in the body. Both the study and the usual radiation treatments use daily images to guide the radiation treatment to protect normal tissue. The study treatment, treatment over a shorter amount of time, may prevent the tumor from returning but it could also cause side effects. This study will allow the researchers to know whether this different approach using SBRT is better, the same, or worse than the usual approach. To be better, the study treatment should increase the time without the cancer coming back by six months or more compared to the usual approach, and show improvements in side effects to the bladder or rectum.
The purpose of this study is to compare any good and bad effects of using stereotactic body radiation therapy (SBRT), a technique that gives treatment in a shorter amount of time compared to the usual radiation therapy. SBRT is experimental for treating this type of cancer. SBRT uses special equipment to position a participant and precisely deliver radiation to tumors in the body. Both the study and the usual radiation treatments use daily images to guide the radiation treatment to protect normal tissue. The study treatment, treatment over a shorter amount of time, may prevent the tumor from returning but it could also cause side effects. This study will allow the researchers to know whether this different approach using SBRT is better, the same, or worse than the usual approach. To be better, the study treatment should increase the time without the cancer coming back by six months or more compared to the usual approach, and show improvements in side effects to the bladder or rectum.
Previously untreated localized adenocarcinoma of the prostate
Clinical stage by digital rectal exam of either T1c or T2a/b
The prostate volume must be < 60 cc as reported at time of biopsy or by separate measure with ultrasound or other imagining modalities including MRI or CT scan
Age is 18 years or older
Definitive T3 disease on MRI
Prior or current invasive malignancy with current evidence of active disease within the past 3 years
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable; must be off treatment
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
The Role of Prediction in Understanding Spoken Language
In this study, we are studying how listeners use information in spoken language to anticipate upcoming information. We study this in typical listening conditions (e.g., when others are speaking simultaneously).
In a single visit lasting between 60 ~ 90 minutes, you will be asked to listen to speech played over headphones and verify/click on the pictures on the screen if they are mentioned. While you do so, your gaze behavior will be tracked. At the end, we will ask you questions about your general language history and complete answer some simple questions about words and sentences.
18
Working Knowledge of English
No History of Language or Speech Disorders
History of Language or Speech Disorders
Development of AI-Trust Model in Electronic Finances
The purpose of this study is to create a model that can predict a quantifiable change in human trust based on the performance of artificial intelligence. This is done through a 30 turn financial simulation where participants must invest "money" in stocks while being given the option to use or not use the assistance of an artificial intelligence.
18 years of age or older
Access to a computer
17 years of age or younger
No access to a computer
(NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB (PSCI# 19-109) (A031704)
The purpose of this study is to compare the usual treatment of advanced kidney cancer (treatment with ipilimumab and nivolumab followed by nivolumab alone) to the usual treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib. This study will help the study doctors find out if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking to see if adding cabozantinib to nivolumab can increase the percentage of patients alive at 3 years from 60% to 70%.
We are asking you to take part in a research study. We do research studies to try to answer questions about how to prevent, diagnose, and treat diseases like cancer.We are asking you to take part in this research study because you have advanced or metastatic kidney cancer.
Age ≥ 18 years
Karnofsky performance status greater than or equal to 70%
Hemoglobin ≥8 g/dL
Platelet Count ≥ 100,000/mm3
No cancer therapy less than 28 days prior to registration; this includes radiation therapy.
Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects.
No history of HIV or active hepatitis B/C, or tuberculosis
No uncontrolled hypertension (systolic BP >150mmHg or diastolic BP
Pain and the Brain in Different Virtual Reality Environments
Research has shown that exposure to different environments alters perceived pain intensity. To explore whether pain differs in various VR environments, we are going to use virtual reality to immerse participants in different settings. At the end of every immersion, we are going to induce controlled experimental thermal pain to participants (like holding a hot cup of coffee) to understand whether their pain differs. We are also going to measure their stress, affect and brain activity using behavioral, electrophysiological (skin conductance and heart rate) and functional Near-Infrared Spectroscopy (fNIRS) methodology. The results have the potential to improve pain treatment in medical settings, where virtual reality is regularly used as a non-pharmacological analgesic, but also to inform architectural design and urban planning, so our cities and homes promote improved pain outcomes.
There will be one in-person visit that will last ~3.5 hours. During the visit you will be immersed in Virtual Reality environments, you will experience painful (but tolerable) heat stimulations, like holding a hot cup of coffee, and you will be asked to rate your pain intensity. We will record your brain activity using functional Near Infrared Spectroscopy (fNIRS) as well as your palm sweatiness and pulse. You will be compensated $25 per hour for your time.
~$85
Fluent English speakers.
Living in the U.S.
Born in the United States or moved to the United States prior to 10 years of age.
Do not have a history of vertigo, motion or simulation sickness.
Pregnancy.
Current presence of pain.
Self-reported color blindness.
Recent history (within two years) of myocardial infarction.
A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects with Nonalcoholic Steatohepatitis and Fibrosis
To evaluate the effect of Saroglitazar Magnesium compared with Placebo on liver scarring in patients with NASH.
There will be 11 in person visits, various procedures will be completed such as a fibroscan, liver biopsy, blood draws and DXA scan. You will be randomly assigned by chance (like the flip of a coin) to receive either Saroglitazar 4 mg or Saroglitazar 2 mg or placebo (inactive substance).
1,325
NASH diagnosis
Stage 2 or 3 fibrosis
Chronic alcohol or drug abuse
Cirrhosis
Inability to provide informed consent
history of liver transplant
Designing for Supportive Accountability: Using Conversational Agents to Sustain Patient Engagement in PTSD
The purpose of this study is to better understand the use and acceptance of conversational agents (CAs) aiming to support individuals with post-traumatic stress disorder (PTSD). Specifically, we will focus on examining CA prototypes that can provide useful information and support individuals with PTSD while sustaining adherence and engagement. This study corresponds to Phase 1 of the NSF grant (e.g., participatory design). The outcomes of the study will be used to advance to Phase 2 of the grant (i.e., system development"). A separate IRB application will be submitted for Phase 2. Toward this goal, we will interview individuals living with PTSD to assess the feasibility, acceptability, and correctness of the prototype of CAs.
1. Individuals who self-report having been diagnosed with PTSD2. Participants are adults, aged 18 years or older.
$30 gift card
Adults, aged 18 years or older.
Participants pass the screening test (the Primary Care PTSD Screen for DSM-5(PC-PTSD-5) and PTSD Checklist for DSM-5 (PCL-5)) identifying whether a participant have PTSD based on self-reported scales
English-speaking participants
von Willebrand Factor in Pregnancy (VIP) Study: A Multicenter Study of Wilate Use in von Willebrand Disease for Childbirth
Specific guidance is lacking for pregnant women with von Willebrand Disease (VWD) and delivery planning in terms of how high a von Willebrand factor (VWF) level should be achieved. Specifically, guidance is lacking on whether replacement therapy drugs (Wilate & Tranexamic Acid) should target a VWF minimum level. This study is a prospective study to document the rate of primary postpartum hemorrhage (PPH) and the effectiveness of the dosing of Wilate, looking to provide increased management and guideline recommendations.
Pregnant women will come to clinic at 34-38 weeks of pregnancy, observation at time of labor or C-Section, during delivery,72 hrs. post delivery & 5-7 days vaginal delivery or 7-10 days if C-Section.
Type I National Heart, Lung & Blood Institute criteria
Gestational weeks 34-38
Presence of liver or renal disease
Suspicion or diagnosis of preeclampsia or eclampsia, HELLP syndrome, TTP or DIC
PSCI 24-114: A Phase II Study Of Tailored Adjuvant Therapy In Pole-Mutated And P53- Wildtype/NSMP Early-Stage Endometrial Cancer (Rainbow Blue & Taper)
This study is to find out if there are types of early-stage endometrial cancer that require less treatment than the usual approach. Based on laboratory testing of the cancer and the extent of spread at time of surgery. The study doctor may recommend Sub-study A or Sub-study B. Based on this assessment, subjects may receive no therapy (observation) or less therapy (de-escalated therapy) than the subject would have received as part of your usual treatment.
Treatment that will be recommended to the subject will be based on laboratory testing of the cancer and the extent of spread at time of surgery. The study doctor might recommend that the subject participate in Sub-study A or Sub-study B. Based on this assessment, the subject may receive no therapy (observation) or less therapy (de-escalated therapy) than the subject would have received as part of their usual treatment After the subject finishes study treatment, and even if they stop treatment early, the study doctor will continue to follow the subject's condition, watch the subject for side effects and keep track of the subjects health. The subject will be seen after 3 months and 6 months, then every 6 months for 3 years, and then every year after starting the study until the study closes. The subject may be seen more often if subject's study doctor thinks it is necessary.
Patients’ Eastern Cooperative Group (ECOG) performance status must be 0, 1, or 2.
Patients’ age must be greater than18 years.
Patients must have had surgery consisting of hysterectomy (total abdominal, laparoscopic or robotic-assisted) and bilateral salpingo-oophorectomy. Lymph node dissection can be performed as per institutional standards (sentinel or full lymphadenectomy)
HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
Prior pelvic radiation.
Clinical evidence of distant metastasis as determined by pre-surgical or post-surgical imaging (CT scan of chest, abdomen and pelvis or whole-body PET-CT scan)
Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥ 5 years.
22-061 Relugolix Versus Leuprolide in Patients with Prostate Cancer: A Randomized, Open-Label Study to Assess Major AdverseCardiovascular Events (REPLACE-CV)
The purpose of this research study is to compare and see if medications used in ADT treatment, either relugolix or leuprolide acetate, lower the risk of cardiovascular events in patients with prostate cancer. You (or your caregiver) will be asked to complete questionnaires electronically (such as computer, tablet, or smartphone) and/or share information via phone calls every three months until the end of your participation in the study. You will receive the study medications for treatment (either relugolix or leuprolide acetate)
Participants will be required to complete questionnaires electronically (such as computer, tablet, or smartphone) and/or share information via phone calls every three months until the end of your participation in the study. You will receive the study medications for treatment (either relugolix or leuprolide acetate)
$150 per year
Is a male and 18 years of age or older on the day of signing and dating the informed consent form;
Patient has sufficient cognitive function in the investigator’s opinion to complete the questionnaires and other activities related to the study
Has histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate
Is, in the opinion of the investigator, a candidate for at least 1 year of continuous ADT for the management of prostate cancer with one of the following clinical disease state presentations:Evidence of biochemical (prostate-specific antigen
Any major cardiovascular or cerebrovascular procedures planned within 1 month after enrollment;
Patients with QT interval corrected for heart rate (QTc) determined using Fridericia’s formula (QTcF; QTcF = QT/[R-R interval {RR}^0.33]) > 470 msec within 6 months of screening
Uncontrolled hypertension (systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg) at the time of screening
Previously received GnRH receptor agonist
POE23-01 - TINI 2: Total Therapy for Infants with Acute Lymphoblastic Leukemia II
This study is being done to improve upon the previous TINI study treatment. It replaces one of the chemotherapy cycles with a type of immunotherapy called blinatumomab. The use of blinatumomab in this study is investigational. In addition, infants that have persistent disease will receive a new investigational drug called ziftomenib that specifically targets infant ALL cells.
You will have exams, tests, and procedures while on the study to evaluate whether you can participate in the study and how you are doing while on the study. These include physical exams, blood tests, urine tests, bone marrow aspirate and biopsies, heart tests, lumbar puncture, and chest x-ray.Treatment on this study from Day 1 of Remission Induction period through the end of Maintenance period will last almost 2 years. After study treatment is completed, you will have blood tests and other evaluations. You will be seen every 4 months for the first year, every 6 months for the second year, and then once a year for up to 10 years.
Newly diagnosed CD19 positive acute lymphoblastic leukemia (ALL) or acute undifferentiated leukemia.
Limited prior therapy
Patients with mature B-cell ALL that does not have a KMT2Ar or patients with acute myelogenous (AML) or T-cell ALL
Patients with Down syndrome
Characterizing resilience to food-cue induced overeating in children
This is a behavioral and neuroimaging study that will examine how food commercials affect the way a child eats and responds to food. Children enrolled in the study will complete 5 in-lab sessions that include eating meals and snacks, watching TV, and playing computer games. For one of these sessions, children will complete an fMRI scan. On the first and last visit to the lab, children will receive a DXA scan to assess their body composition.
We are looking for children to help us learn about how kids respond to different types of foods and food advertisements. The study consists of 5 visits to our facilities in Noll and Chandlee Labs, located on the University Park Campus. For 3 visits your child will eat test meals and snack buffets in our laboratory. On 1 visit we will use fMRI to take pictures of your child’s brain. We will use a DXA to scan for lean muscle and conduct an IQ test. These procedures are not harmful. You and your child will fill out questionnaires.Your child will also play computer games and watch commercials.
$250.00-450.00
Be 7-9 years-old at enrollment.
Not be taking any medications known to influence body weight, taste, food intake, behavior, or blood flow.
Have no learning disabilities (e.g., ADHD).
The biological mother must have a body mass index either between 18.5 - 25 kg/m2 (low-risk group) or greater than or equal to 30 kg/m2 (high-risk group).
If they have a learning disability, ADD/ADHD, language delays, autism or other neurological or psychological conditions.
If they have a pre-existing medical condition such as diabetes, rheumatoid arthritis, Cushing’s syndrome, Down’s syndrome, severe lactose intolerance, Prader-Willi syndrome, HIV, cancer, renal failure, cerebral palsy, or can't engage in moderate exercise.
If they don’t speak English.
Biological mother must have a body mass index either between 18.5 - 25 kg/m2 (low-risk group) or greater than or equal to 30 kg/m2 for mothers (high-risk group), or they are excluded.
Emotion dynamics and alcohol use in NIAAA-defined recovery from alcohol use disorder
This study uses a baseline assessment and 28 days of ecological momentary assessment to examine the association of emotion dynamics to craving and alcohol use among people in the first year of cessation of heavy drinking and remission from DSM-5 AUD.
There will be one in person visit. Participants will be asked to complete baseline questionnaires. After the baseline assessment, participants will complete 28 days of daily diary questions on their cell phone. A prompt will be sent to the phone 3 times per day. It should take 5 minutes (15 minutes total/day) to complete the questions.
184
Have a history of a previous (AUD) in the past year
Live within commuting distance of the Penn State Clinical Research Center
Bipolar disorder
Cognitive impairment
Active drug use disorder other than nicotine or cannabis dependence
Lack of sufficient familiarity with the English language to comprehend recruitment and consent procedures
The Sexual Relationships Study
The purpose of this study is to examine the sexual relationships among heterosexual female college students (ages 18-22) via Qualtrics (a web-based survey). Utilizing latent class analysis with a distal outcome, the proposed cross-sectional study seeks to do the following: Aim 1. Examine the heterogeneity in relationship quality among female college students. Research question 1: Is there a latent class structure that adequately represents the heterogeneity in relationship quality among female undergraduate students participating in penile-vaginal sex? If so, what are the types and their corresponding prevalence?Aim 2. Examine the association between relationship characteristics and latent class membership.Research question 2: Are relationship characteristics (partner type, relationship duration, exclusivity/monogamy, and frequency of sex) predictive of membership in latent classes of relationship quality?Aim 3. Examine the association between latent classes of relationship quality and condom use.Research question 3: Which identified latent class of relationship quality is significantly associated with condom use at last penile-vaginal sex?Please note that the indicators measuring relationship quality will include the following variables: 1) trust, 2) love, 3) passion, 4) commitment, 5) relationship satisfaction, 6) sexual satisfaction, 7) intimacy, and 8) decision-making dominance.
Be between the ages of 18-22 years
Be a female college student
Be sexually active with male partners in the previous 3 months
Are under the age of 18 or over the age of 22.
Are not a female college student
Are not sexually active with male partners in the previous 3 months
NMTRC014: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
A study of DFMO for patients with neuroblastoma in remission.
Participating in this study requires that you visit the Penn State health Medical Center multiple times over the course of the full study for evaluations (physical exam, blood draw, urine analysis, etc.) and scans (MRI/CT, MIBG).If you agree to take part, you will receive treatment on this study for about 2 years and will be followed for survival for 5 years after the last dose of study drug. You will be asked to return to the research site approximately 15 times.
Must be in complete remission (CR).
Tests and scans will be required to confirm remission.
Patients who are currently receiving another study drug may not participate.
Patients who are currently receiving other anticancer agents may not participate.
Exploring the effects of nighttime indoor light exposure on children with autism spectrum disorder
This study aims to identify potential differences in psychological and physiological responses to indoor light at night and to offer recommendations for optimizing the sleep patterns, circadian rhythms, and sensory regulation of children with ASD.
Parents and/or caregivers of children with ASD will fill out surveys and collect saliva samples.
20
Aged 9-15
Sleep difficulties
Disorders such as sleep apnea, restless legs syndrome, or periodic limb disorder during sleep
Children with fragile X syndrome, Down syndrome, neurofibromatosis, or tuberous sclerosis complex and children who had a non-febrile unprovoked epileptic seizure within the last two years
Contempt as a Mixed Emotion
This study will investigate whether contempt is a positive, negative, or mixed emotion.
Human intent recognition using surface cues in physically dynamic tasks
Prediction of a subject's goal in a task based on patterns in their body language, speech, facial expressions, reaction to outcome, in short any observable measure.
provides consent to record video of the experiment
does not consent to experiment being recorded
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) (EA8143) (PSCI 18-025)
This study is a phase 3 study that will be comparing recurrence-free survival (RFS) between patients withlocally advanced renal cell carcinoma randomly assigned toperioperative nivolumab in conjunction with radical or partialnephrectomy with patients randomized to surgery alone.
You are being asked to take part in this research study because you have cancer in your kidney, which is planned to be removed by a surgeon. The standard treatment for your disease is to remove the kidney or part of the kidney that contains the cancer by surgery. You are then monitored after surgery with imaging scans and exams to watch for any possiblesigns of recurrence (close observation)
No clinical or radiological evidence of distant metastases
No concurrent or prior systemic or local anti-cancer therapy for RCC is permitted
Age must be greater than or equal to 18 years old
ECOG Performance status must be 0 or 1
History of RCC that was resected with curative intent within the past 5 years
Prior or current prostate cancer is excluded
Active known or suspected autoimmune disease
Uncontrolled adrenal insufficiency
PSCI 22-156 HCRN BRE17-141
The purpose of this voluntary research study is to see if neratinib, endocrine therapy, and trastuzumab completely shrink breast tumors before having breast cancer surgery. You will need to have the following exams, tests, or procedures: blood draws, ECG, Echo or MUGA, ultrasound, MRI, receive study treatment, and breast biopsy.
Participants will be required to receive study treatments, laboratory assessments, undergo breast biopsy, and radiologic assessments,
HER2-positive (by most recent ASCO-CAP criteria)
ER > 50% and PR > 50%.
Resectable breast cancer in which pre-operative therapy is appropriate (T > 10mm and/or node-positive).
Archival tissue from the diagnostic pre-treatment biopsy is required.
Evidence of metastatic disease.
Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are not eligible for this trial:
Active infection requiring systemic therapy.
Requirement for use of a moderate or strong CYP3A4 inhibitor or inducer during the study
Collective Punishment and Identity Fusion: An Examination
This study, part of a broader dissertation on terrorism and radicalization, aims to experimentally determine how collective punishment fuses individual identities to that of an ingroup, expanding extant knowledge of identity fusion theory.
Identification as Republican or Democratic
English Speaker
Political identification as independent (not republican or democrat)
Non-English Speakers
BCC020: A Dose Escalation Study Using Difluoromethylornithine(DFMO) and AMXT-1501 followed by a Randomized Controlled Trial of DFMO with or without AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas
The purpose of this study is to evaluate the investigational drug AMXT-1501 (a pill taken by mouth) in combination with the study drug difluoromethylornithine (DFMO) for infusion administered intravenously (IV; a liquid that continuously goes into your body through a tube that has been placed during a surgery into one of your veins). An investigational drug is one that has not been approved by the U.S. Food & Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat.
You will undergo a number of standard tests and research-related procedures before being able to enroll on this study.